MedPath

Baxalta Innovations GmbH

🇦🇹Austria
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.baxalta.at

Clinical Trials

153

Active:145
Completed:1

Trial Phases

4 Phases

Phase 1:132
Phase 3:9
Phase 4:2
+1 more phases

Drug Approvals

39

CIMA_AEMPS:25
SFDA:9
EMA:5

Drug Approvals

Veyvondi

Authorization Status
Authorised
Approval Date
Aug 31, 2018
EMA

Adynovi

Authorization Status
Authorised
Approval Date
Jan 8, 2018
EMA

Obizur

Authorization Status
Authorised
Approval Date
Nov 11, 2015
EMA

Rixubis

Authorization Status
Authorised
Approval Date
Dec 19, 2014
EMA

HyQvia

Authorization Status
Authorised
Approval Date
May 16, 2013
EMA

Clinical Trials

Distribution across different clinical trial phases (144 trials with phase data)• Click on a phase to view related trials

Phase 1
132 (91.7%)
Phase 3
9 (6.3%)
Phase 4
2 (1.4%)
Not Applicable
1 (0.7%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.